Nyheter om approval

Nedan listas samtliga nyheter som behandlar approval:

Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe >

Nyheten uppdaterades 2013-06-28 14:50

– CHMP also Recommends NAS Designation for AUBAGIO® (teriflunomide) Following Positive Opinion on Approval in March 2013 – – Positive Opinions Set Stage for Introduction of Two New Genzyme Therapies for Multiple Sclerosis in Europe –   Cambridge,…

Corline’s heparin technology makes front page >

Nyheten uppdaterades 2013-06-25 13:20

Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has had a study of its  technology published in the leading scientific journal Tissue Engineering. The editors chose to place it front page. “Obviously, the inherent capability of our technology to promote cells to […]

Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes >

Nyheten uppdaterades 2012-06-20 10:07

– Research collaboration with affiliate of Harvard Medical School aims to develop novel therapeutic approaches – Paris, France – June 19, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, today announced a new collaboration to promote the development of new medicines…

Corline’s IP portfolio further strengthened by EU patent >

Nyheten uppdaterades 2012-02-20 16:27

Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has been granted approval for Patent Application EPO No. 06 748 063.2 – 2112 by the European Patent Office.  “With this newly granted EU patent, Corline has secured IP protection for its core Regenerative Medicine technology […]

Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista(R) >

Nyheten uppdaterades 2012-02-20 15:30

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has entered into a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a new fixed-dose antiretroviral combination product containing Gilead’s cobicistat and Tibotec’s protease inhibitor Prezista(R) (darunavir). Cobicistat is an investigational pharmacoenhancing or ”boosting” agent that increases blood levels of certain HIV medicines to […]

Rebif® godkänt för behandling efter första skovet vid Multipel Skleros >

Nyheten uppdaterades 2012-02-06 15:38

January 25, 2012 Merck Serono Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis. Geneva, Switzerland, January 25, 2012 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) has approved extension of the indication of Rebif (interferon beta-1a), Merck Serono’s leading treatment […]